Tackling hepatocellular carcinoma with individual or combinatorial immunotherapy approaches

Maria Tagliamonte, Angela Mauriello, Beatrice Cavalluzzo, Concetta Ragone, Carmen Manolio, Annacarmen Petrizzo, Luigi Buonaguro

Research output: Contribution to journalShort surveypeer-review


Hepatocellular carcinoma (HCC) is the third leading cause of death from cancer globally. Indeed, there is a single drug approved as first-line systemic therapy in advanced unresectable HCC, providing a very limited survival benefit. In earlier stages, 5-year survival rates after surgical and loco-regional therapies are extremely variable depending on the stage of disease. Nevertheless, HCC is considered an immunogenic tumor arising in chronically inflamed livers. In such a scenario, immunotherapy strategies for HCC, in particular combinations including cancer vaccines, may represent a key therapeutic tool to improve clinical outcome in HCC patients. However, a lot of improvement is needed given the disappointing results obtained so far.

Original languageEnglish
Pages (from-to)25-32
Number of pages8
JournalCancer Letters
Publication statusPublished - Mar 31 2020


  • Cancer vaccine
  • Checkpoint inhibitors
  • Epigenetic drugs
  • Immunotherapy
  • Liver cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Tackling hepatocellular carcinoma with individual or combinatorial immunotherapy approaches'. Together they form a unique fingerprint.

Cite this